title: Duration of treatment for osteoporosis.
abstract: Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness.
authors.affiliation: Rheumatology Unit, University of Verona, Verona, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Idolazzi
authors.forename: A
authors.initials: A
authors.lastname: Fassio
authors.forename: D
authors.initials: D
authors.lastname: Gatti
authors.forename: S
authors.initials: S
authors.lastname: Tamanini
authors.forename: O
authors.initials: O
authors.lastname: Viapiana
authors.forename: M
authors.initials: M
authors.lastname: Rossini
authors.forename: S
authors.initials: S
authors.lastname: Adami
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology / Q000517:prevention & control; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001862:Bone Resorption / Q000517:prevention & control; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004363:Drug Utilization; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators